Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, US

Chairman and Chief Executive Officer

Boston Scientific Corporation has offices in Marlborough, Voisins-le-Bretonneux, Singapore, Arden Hills and in 7 other locations

Marlborough, US (HQ)

100 Boston Scientific Way

Sandton, ZA

Anslow Ln

Üsküdar, TR

45 Ord. Prof. Dr. Fahrettin Kerim Gökay Cd.

Gurugram, IN

48 Sohna Rd

Maple Grove, US

1 Scimed Pl

Huangpu Qu, CN

Meng Zi Lu

Boston Scientific Corporation's revenue was reported to be $8.4 b in FY, 2016 which is a **12% increase** from the previous period.

USD

## Revenue (FY, 2016) | 8.4 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 12% |

## Gross profit (FY, 2016) | 6 b |

## Gross profit margin (FY, 2016), % | 71% |

## Net income (FY, 2016) | 347 m |

## EBIT (FY, 2016) | 447 m |

## Market capitalization (18-Aug-2017) | 37.4 b |

## Cash (31-Dec-2016) | 196 m |

## EV | 42.6 b |

Boston Scientific Corporation's current market capitalization is $37.4 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 7.1 b | 7.4 b | 7.5 b | 8.4 b |

## Revenue growth, % | 3% | 1% | 12% | |

## Cost of goods sold | 2.2 b | 2.2 b | 2.2 b | 2.4 b |

## Gross profit | 5 b | 5.2 b | 5.3 b | 6 b |

## Gross profit Margin, % | 70% | 70% | 71% | 71% |

## EBIT | 120 m | (301 m) | (327 m) | 447 m |

## EBIT margin, % | 2% | (4%) | (4%) | 5% |

## Pre tax profit | (223 m) | (509 m) | (650 m) | 177 m |

## Net Income | (121 m) | (119 m) | (239 m) | 347 m |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 217 m | 587 m | 319 m | 196 m |

## Inventories | 897 m | 946 m | 1 b | 955 m |

## Current Assets | 3 b | 3.6 b | 3.5 b | 3.2 b |

## PP&E | 1.5 b | 1.5 b | 1.5 b | 1.6 b |

## Goodwill | 5.7 b | 5.9 b | 6.5 b | 6.7 b |

## Total Assets | 16.6 b | 17 b | 18.1 b | 18.1 b |

## Accounts Payable | 246 m | 262 m | 209 m | 447 m |

## Total Debt | 4.2 b | 3.9 b | 5.7 b | 5.4 b |

## Current Liabilities | 1.8 b | 2.8 b | 2.4 b | 3.6 b |

## Additional Paid-in Capital | 16.6 b | 16.7 b | 16.9 b | 17 b |

## Retained Earnings | (8.6 b) | (8.7 b) | (8.9 b) | (8.6 b) |

## Total Equity | 6.5 b | 6.5 b | 6.3 b | 6.7 b |

## Debt to Equity Ratio | 0.6 x | 0.6 x | 0.9 x | 0.8 x |

## Debt to Assets Ratio | 0.3 x | 0.2 x | 0.3 x | 0.3 x |

## Financial Leverage | 2.5 x | 2.6 x | 2.9 x | 2.7 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (121 m) | (119 m) | (239 m) | 347 m |

## Accounts Receivable | (101 m) | 53 m | (17 m) | (216 m) |

## Inventories | (7 m) | (81 m) | 3 m | 40 m |

## Accounts Payable | (37 m) | 620 m | (20 m) | 553 m |

## Cash From Operating Activities | 1.1 b | 1.3 b | 600 m | 972 m |

## Purchases of PP&E | (245 m) | (259 m) | (247 m) | (376 m) |

## Interest Paid | 329 m | 221 m | 283 m | 233 m |

## Income Taxes Paid | 67 m | 74 m | 80 m | 94 m |

USD | Y, 2016 |
---|---|

## EV/EBIT | 95.4 x |

## EV/CFO | 43.9 x |

## Revenue/Employee | 322.5 k |

## Debt/Equity | 0.8 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 2.7 x |

Boston Scientific Corporation's Customers was reported to be 35 k in FY, 2016

- Source: SEC Filings

Acquired Company | Date | Deal Size |
---|---|---|

Symetis | March 30, 2017 | $435 m |

Source: 206 public H-1B filings from Boston Scientific Corporation

October 01, 2016

Since 2012, deals to early-stage medical device companies have hovered around 30% of total deal volume to the category. VCs and corporate investors alike are continuing to fund medical device startups in 2016 and the category is on track to see another year of increased … Continued

September 15, 2016

Medical device funding is on track to reach $3.5B in 2016, a slight increase over last year’s dollar total. Since 2012, most funding to medical device startups has occurred in the United States, with NEA leading venture capital activity and Johnson & … Continued

August 23, 2016

Corporations and their investment arms — including Johnson & Johnson, Kaiser Permanente, and Medtronic — have been participating in major deals to medical device startups. These include large late-stage deals into CVRx, Acutus Medical, and Transmedics. Additionally, deals with corporate backing …